Modifying Factors in Striated Muscle Laminopathies
NCT05394506
Autosomal Emery-Dreifuss Muscular Dystrophy, Cardiomegaly
Bron, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT Number: NCT03058185
Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the description of the clinical and genetic spectrum of these diseases since the 1990's. Until now, precise phenotype/genotype relations remain elusive. As for several other neuromuscular disorders, apart from symptomatic treatments, there is currently no specific treatment to prevent or slow down the progression of the disease. The OPALE registry is a multicentre web-based registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved by ethical and regulatory authorities. Its main inclusion criteria is the presence of a proven pathogenic LMNA and/or EMD gene mutation.
The OPALE objectives are to provide a tool allowing detailed capture of patient genetic, neurological, cardiological, endocrinological and respiratory assessments, in order to allow i) precise disease natural history, ii) evaluation of different disease complication frequency and iii) identification of prognosis factors.
Interested in participating?
Request InfoAll sexes
Observational
Centre de référence maladies neuromusculaires,CHU d'Angers, Angers, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-Refusal to sign an informed consent.
Time frame: yearly up to 10 years
Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression
Contact information is provided by the study sponsor or research team.
Cathy Chikhaoui
CONTACT
Hassina Bouguerra
CONTACT
Pitié-Salpêtrière Hospital
Other
Acronym: OPALE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05394506
Autosomal Emery-Dreifuss Muscular Dystrophy, Cardiomegaly
Bron, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT06813443
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Bologna, Emilia-Romagna/Bologna, Italy
View Trial DetailsNCT01403402
Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)
Lakewood, California, United States
View Trial DetailsNCT05099107
Centronuclear Myopathy, Congenital Myopathy
Gothenburg, Västra Götaland County, Sweden
View Trial Details